Biopharma Can Reduce the Cost of Bringing A Treatment to Market by More Than US$1 Billion, According to Accenture Report
NEW YORK; Oct. 26, 2021 – A new report from Accenture (NYSE: ACN) identifies three steps biopharmaceutical organizations could take to reduce the average cost of discovering and developing a treatment by more than US$1 billion. Furthermore, it could potentially create additional future revenue opportunities of up to US$450 million per treatment.
Comments
Post a Comment